
Mahmoud M Shehata

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1224184/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Eurosurveillance, 2013, 18, pii=20574.	7.0	278
2	MERS Coronaviruses in Dromedary Camels, Egypt. Emerging Infectious Diseases, 2014, 20, 1049-1053.	4.3	259
3	FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2. Pharmaceuticals, 2020, 13, 443.	3.8	110
4	Active Surveillance for Avian Influenza Virus, Egypt, 2010–2012. Emerging Infectious Diseases, 2014, 20, 542-551.	4.3	71
5	Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies. Heliyon, 2021, 7, e07962.	3.2	62
6	Genetic and antigenic evolution of H9N2 avian influenza viruses circulating in Egypt between 2011 and 2013. Archives of Virology, 2014, 159, 2861-2876.	2.1	58
7	Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt. Emerging Microbes and Infections, 2017, 6, 1-7.	6.5	55
8	Naturally Available Flavonoid Aglycones as Potential Antiviral Drug Candidates against SARS-CoV-2. Molecules, 2021, 26, 6559.	3.8	54
9	Middle East respiratory syndrome coronavirus: a comprehensive review. Frontiers of Medicine, 2016, 10, 120-136.	3.4	49
10	Coding-Complete Genome Sequences of Two SARS-CoV-2 Isolates from Egypt. Microbiology Resource Announcements, 2020, 9, .	0.6	44
11	Strong Inhibitory Activity and Action Modes of Synthetic Maslinic Acid Derivative on Highly Pathogenic Coronaviruses: COVID-19 Drug Candidate. Pathogens, 2021, 10, 623.	2.8	44
12	Middle East respiratory syndrome coronavirus infection in non-camelid domestic mammals. Emerging Microbes and Infections, 2019, 8, 103-108.	6.5	42
13	Isolation and Characterization of a Distinct Influenza A Virus from Egyptian Bats. Journal of Virology, 2019, 93, .	3.4	42
14	Cross-sectional surveillance of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels and other mammals in Egypt, August 2015 to January 2016. Eurosurveillance, 2017, 22,	7.0	41
15	Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Dromedary Camels in Africa and Middle East. Viruses, 2019, 11, 717.	3.3	38
16	Bacterial Outer Membrane Vesicles (OMVs)-Based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV. Vaccines, 2019, 7, 46.	4.4	38
17	Itaconate and derivatives reduce interferon responses and inflammation in influenza A virus infection. PLoS Pathogens, 2022, 18, e1010219.	4.7	35
18	Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. Vaccines, 2021, 9, 214.	4.4	33

MAHMOUD M SHEHATA

#	Article	IF	CITATIONS
19	Middle East Respiratory Syndrome Coronavirus (MERS-CoV): State of the Science. Microorganisms, 2020, 8, 991.	3.6	30
20	Evidence of infection with avian, human, and swine influenza viruses in pigs in Cairo, Egypt. Archives of Virology, 2018, 163, 359-364.	2.1	24
21	In Silico and In Vivo Evaluation of SARS-CoV-2 Predicted Epitopes-Based Candidate Vaccine. Molecules, 2021, 26, 6182.	3.8	23
22	Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort. PLoS Pathogens, 2021, 17, e1009413.	4.7	21
23	Complete Genome Sequence of Middle East Respiratory Syndrome Coronavirus Isolated from a Dromedary Camel in Egypt. Genome Announcements, 2016, 4, .	0.8	17
24	Surveillance for Coronaviruses in Bats, Lebanon and Egypt, 2013–2015. Emerging Infectious Diseases, 2016, 22, 148-150.	4.3	15
25	Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses. Vaccine, 2016, 34, 218-224.	3.8	13
26	PA from a Recent H9N2 (G1-Like) Avian Influenza A Virus (AIV) Strain Carrying Lysine 367 Confers Altered Replication Efficiency and Pathogenicity to Contemporaneous H5N1 in Mammalian Systems. Viruses, 2020, 12, 1046.	3.3	12
27	Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002. Frontiers in Microbiology, 2021, 12, 611958.	3.5	12
28	Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2. PLoS ONE, 2020, 15, e0241471.	2.5	11
29	Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease. Bioorganic Chemistry, 2021, 116, 105363.	4.1	10
30	Anticancer activities of mushroom polysaccharides on chemically-induced colorectal cancer in rats. Journal of Applied Pharmaceutical Science, 2014, 4, .	1.0	9
31	Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors. Frontiers in Microbiology, 2020, 11, 596851.	3.5	7
32	NextGen Voices: Science-inspired sustainable behavior. Science, 2019, 364, 822-824.	12.6	6
33	A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice. Pathogens, 2019, 8, 281.	2.8	4
34	Evolution of H5-Type Avian Influenza A Virus Towards Mammalian Tropism in Egypt, 2014 to 2015. Pathogens, 2019, 8, 224.	2.8	2